Why Drug Developers Need To Seek Scientific Advice From The EMA
This article was originally published in SRA
Executive Summary
Scientific advice from the European Medicines Agency, whether given alone or in parallel with health technology assessment (HTA) bodies, is an increasingly important factor in whether a new drug makes it through to marketing approval, and can double the likelihood of a positive opinion from the agency's scientific committee, the CHMP.